CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-92480
Other: Placebo

First Posted Date: 2021-04-09

Last Posted Date: 2021-12-10

Lead Sponsor: Celgene

Target Recruit Count: 40

Registration Number: NCT04839809

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Dermatitis, Atopic
Eczema

Interventions: Drug: CC-93538
Other: Placebo

First Posted Date: 2021-03-16

Last Posted Date: 2024-01-03

Lead Sponsor: Celgene

Target Recruit Count: 221

Registration Number: NCT04800315

Locations: 🇺🇸
Local Institution - 125, Silver Spring, Maryland, United States
🇨🇦
Dr. Chih-ho Hong Medical Inc., Surrey, British Columbia, Canada
🇨🇦
Local Institution - 213, Edmonton, Alberta, Canada

and more 153 locations

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Leukemia, Myeloid

Interventions: Drug: CC-96191

First Posted Date: 2021-03-09

Last Posted Date: 2025-05-31

Lead Sponsor: Celgene

Target Recruit Count: 45

Registration Number: NCT04789655

Locations: 🇫🇷
Local Institution - 302, Villejuif CEDEX, France
🇫🇷
Local Institution - 304, Paris, France
🇫🇷
Local Institution - 301, Pessac Cedex, France

and more 11 locations

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Conditions: Multiple Myeloma

First Posted Date: 2021-02-25

Last Posted Date: 2023-01-23

Lead Sponsor: Celgene

Registration Number: NCT04771078

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Phase 3

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Other: Placebo
Drug: CC-93538

First Posted Date: 2021-02-15

Last Posted Date: 2025-03-13

Lead Sponsor: Celgene

Target Recruit Count: 430

Registration Number: NCT04753697

Locations: 🇺🇸
Local Institution - 092, Denver, Colorado, United States
🇺🇸
Local Institution - 170, Littleton, Colorado, United States
🇺🇸
Local Institution - 046, Florence, Kentucky, United States

and more 209 locations

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Phase 1

Terminated

Conditions: Leukemia, Myeloid

Interventions: Drug: CC-90011
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2021-02-10

Last Posted Date: 2023-03-02

Lead Sponsor: Celgene

Target Recruit Count: 1

Registration Number: NCT04748848

Locations: 🇺🇸
Local Institution - 121, New York, New York, United States
🇪🇸
Local Institution - 802, Madrid, Spain
🇺🇸
Local Institution - 104, Dallas, Texas, United States

and more 14 locations

A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Device: MyHOPE™ for Multiple Myeloma
Device: MyHope HCP Portal

First Posted Date: 2021-01-29

Last Posted Date: 2021-08-09

Lead Sponsor: Celgene

Target Recruit Count: 2

Registration Number: NCT04730505

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 31 locations

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Phase 3

Active, not recruiting

Conditions: Myeloproliferative Disorders
Myelofibrosis
Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Anemia

Interventions: Drug: ACE-536
Other: Placebo

First Posted Date: 2021-01-22

Last Posted Date: 2025-03-14

Lead Sponsor: Celgene

Target Recruit Count: 309

Registration Number: NCT04717414

Locations: 🇺🇸
University Of California Los Angeles, Los Angeles, California, United States
🇺🇸
BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸
Local Institution - 112, Chicago, Illinois, United States

and more 205 locations

A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)
Drug: CC-99677

First Posted Date: 2021-01-22

Last Posted Date: 2021-10-28

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT04718636

Locations: 🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
🇺🇸
Hassman Research Institute, Marlton, New Jersey, United States
🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Fedratinib
Drug: Fluconazole

First Posted Date: 2021-01-11

Last Posted Date: 2021-11-29

Lead Sponsor: Celgene

Target Recruit Count: 29

Registration Number: NCT04702464

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy